Predictive OncologyPOAI
About: Predictive Oncology Inc functions in the healthcare domain. The firm's reportable segments are Pittsburgh segment that provides services which include the application of AI using its proprietary biobank of 150,000+ tumor samples. It also creates proprietary 3D culture models used in drug development; Birmingham segment that provides contract services and research focused on solubility improvements, stability studies, and protein production; and Eagan segment that produces the FDA-cleared STREAMWAY System and associated products for automated medical fluid waste management and patient-to-drain medical fluid disposal. It derives maximum revenue from Eagan Segment.
Employees: 35
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
300% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 1
0% more funds holding in top 10
Funds holding in top 10: 1 [Q2] → 1 (+0) [Q3]
4.01% less ownership
Funds ownership: 7.04% [Q2] → 3.03% (-4.01%) [Q3]
6% less funds holding
Funds holding: 18 [Q2] → 17 (-1) [Q3]
25% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 4
48% less capital invested
Capital invested by funds: $300K [Q2] → $157K (-$143K) [Q3]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
HC Wainwright & Co. Swayampakula Ramakanth 35% 1-year accuracy 56 / 159 met price target | 337%upside $3 | Buy Initiated | 19 Aug 2024 |
